This content is machine translated Atopic dermatitis The JAK/STAT pathway as a therapeutic target. Janus kinase (JAK) inhibitors inhibit signal transduction of numerous proinflammatory cytokines with varying selectivity. With baricitinib, upadacitinib and abrocitinib, three oral JAK inhibitors are currently approved in Switzerland for the…
